Short Interest in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Drops By 31.8%

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) was the target of a large decrease in short interest in the month of January. As of January 31st, there was short interest totalling 161,300 shares, a decrease of 31.8% from the January 15th total of 236,500 shares. Approximately 1.1% of the shares of the stock are sold short. Based on an average daily volume of 271,300 shares, the days-to-cover ratio is presently 0.6 days.

NeuroSense Therapeutics Price Performance

Shares of NRSN stock traded down $0.02 during trading hours on Friday, hitting $1.16. The stock had a trading volume of 68,477 shares, compared to its average volume of 164,606. The stock has a market capitalization of $15.79 million, a price-to-earnings ratio of -1.80 and a beta of 1.27. NeuroSense Therapeutics has a one year low of $0.51 and a one year high of $2.33. The stock’s 50-day moving average price is $1.13 and its two-hundred day moving average price is $1.09.

NeuroSense Therapeutics (NASDAQ:NRSN) last released its quarterly earnings data on Wednesday, December 18th. The company reported ($0.11) earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On NeuroSense Therapeutics

An institutional investor recently bought a new position in NeuroSense Therapeutics stock. Jane Street Group LLC bought a new position in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund bought 64,636 shares of the company’s stock, valued at approximately $78,000. Jane Street Group LLC owned about 0.47% of NeuroSense Therapeutics as of its most recent SEC filing. 1.04% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Maxim Group reaffirmed a “hold” rating on shares of NeuroSense Therapeutics in a research note on Monday, December 16th.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.